ClinicalTrials.gg
Active, not recruitingNCT03564873Updated Nov 6, 2026Results posted

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

A Phase 1/2 interventional study of Omacetaxine and Azacitidine in High Grade Myelodysplastic Syndromes, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Colorado, Denver · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
79th of 126
29 · median 38
Started
2018
with 4 others
Phase 1/2
20 of 130
1 open now
Primary completion
2025-10
later than 5 of 24 live
Registered
97th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 79th largest by enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2018, is one of 20 in phase 1/2, reaches primary completion later than 5 of the 24 other live ones, and was the 97th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.

Read the detailed description

This is an open-label, phase I/II study for previously untreated patients with high grade MDS using omacetaxine and azacitidine with a small expansion cohort for relapsed and refractory MDS patients. Phase I features dose escalation, where patients will be assigned to one of three cohorts to receive different doses of omacetaxine with the standard dose and schedule of azacitidine, over a 28 day cycle. Phase II features the maximum tolerated dose from the Phase 1 study. An additional expansion cohort of 10 MDS patients who have failed to respond to or responded and relapsed after at least one line of therapy containing a hypomethylating agent therapy will also be accrued.

03

Conditions studied

  • High Grade Myelodysplastic Syndromes

Keywords

  • Omacetaxine
  • Azacitidine
  • Previously Untreated
  • Phase I/II
  • Dose Escalation
  • Maximum Tolerated Dose
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for study participation if he/she meets the following criteria within 14 days prior to the first day of therapy (bone marrow can be performed 28 days prior to the first day of therapy).

  1. Subject must have confirmation of high grade MDS (MDS with excess blasts by WHO criteria) or chronic myelomonocytic leukemia with greater than 5% bone marrow blasts
  2. Subjects in the newly-diagnosed Phase 2 cohort must have received no prior treatment with a hypomethylating agent for MDS. Subjects in the Phase 2 cohort must have received at least 1 prior line of an HMA-containing regimen. "Refractory" is defined as having received at least four cycles of any HMA or HMA-containing regimen with >5-19% bone marrow blasts. "Relapsed" is defined as having >5-19% bone marrow blasts after having achieved a morphologic remission (≤5% bone marrow blasts) after at least one cycle of any HMA or HMA-containing regimen.
  3. Subject must be ≥ 18 years of age
  4. Subject must have a projected of at least 12 weeks
  5. Subject must have an (ECOG) Performance status of ≤2
  6. Subject must have adequate renal function as demonstrated by a calculated ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula
  7. Subject must have adequate liver function as demonstrated by:

    • (AST) ≤ 3.0 ×
    • alanine aminotransferase (ALT) ≤ 3.0 × ULN
    • direct ≤ 3.0 × ULN
  8. Non-sterile male subjects must use methods with partner(s) from time of enrollment and continuing up to 90 das after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.
  9. Female subjects must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting omacetaxine; 2) throughout the entire duration of omacetaxine treatment; 3) during dose interruptions; and 4) for at least 90 days after omacetaxine discontinuation.
  10. Subject must voluntarily sign and date an , approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for study participation if he/she meets any of the following criteria:

  1. Subject is known to be positive for . HIV testing is not required.
  2. Subject is known to be positive for or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate.
  3. Subject has any history of condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:

    • heart failure > class 2
    • Renal, neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia
  4. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). Patients on antibiotics with controlled systemic symptoms will not be excluded.
  5. Subject has uncontrolled diabetes
  6. Subject has had a recent major hemorrhage or has a bleeding diathesis associated with a high risk of bleeding
  7. Pregnant and breastfeeding females.
  8. Subject has a history of other prior to study entry, except for:

    • Adequately treated in situ carcinoma of the breast or cervix uteri
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
    • Prostate cancer with no plans for therapy of any kind
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Cohort 0: De-Escalation Omacetaxine .5mg/m2

    De-escalation dose if DLTs are experienced for Cohort 1. Dose is Omacetaxine .5mg/m2 subcutaneous BID days 1-7.

    Drug: Omacetaxine · Drug: Azacitidine

  • Experimental
    Cohort 1: Escalation Phase Omacetaxine .75mg/m2

    Patients in Cohort 1 will receive .75mg/m2 subcutaneous BID days 1-7.

    Drug: Omacetaxine · Drug: Azacitidine

  • Experimental
    Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2

    Patients in Cohort 2 will receive 1.0mg/m2 subcutaneous BID days 1-7.

    Drug: Omacetaxine · Drug: Azacitidine

  • Experimental
    Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2

    Patients in Cohort 3 will receive 1.25mg/m2 subcutaneous BID days 1-7.

    Drug: Omacetaxine · Drug: Azacitidine

  • Experimental
    Cohort 4: Expansion Phase Omacetaxine .5mg/m2

    Dosing in Expansion Phase is based on the MTD determined with Cohorts 0-3. MTD was determined to be .5 mg/m2. Patients received .5mg/m2 Omacetaxine BID subcutaneously days 1-7.

    Drug: Omacetaxine · Drug: Azacitidine

  • Experimental
    Cohort 5: Relapse Phase

    Drug: Omacetaxine · Drug: Azacitidine

Interventions

  • DrugHomoharringtonineStudies of HomoharringtonineHomoharringtonine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.

    Also known as: Phase 1

  • Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.

    Also known as: Phase 1

  • DrugHomoharringtonineStudies of HomoharringtonineHomoharringtonine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.

    Also known as: Phase 2

  • Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.

    Also known as: Phase 2

06

What researchers measure

Primary outcomes

  1. Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose

    Determine the recommended dose of omacetaxine based on the maximum tolerated dose. The MTD is defined as the highest dose at which ≤1 patient experiences a DLT in Cycle 1. Count of participants who did not experience a DLT are listed in outcome measure data table.

    Time frame: First treatment through end of Cycle 1 (28 days) only for dose escalation cohorts.

  2. Overall Response Rate

    This was a pre-specified primary outcome measure defined by the proportion of patients who achieve any category of complete remission (CR, includes CR and marrow CR) or partial remission (PR) based on the 2006 International Working Group (IWG) criteria for MDS1.

    Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.

Secondary outcomes

  1. Overall Survival

    Overall survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine to death from any cause.. This will be measured using Kaplan-Meier survival analysis curves.

    Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.

  2. Progression Free Survival

    Progression Free Survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine that a patient lives with the disease but does not get worse. This will be measured using Kaplan-Meier survival analysis curves.

    Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.

  3. Duration of Response

    Duration of Response will be defined as Time from documentation of tumor response to disease progression.This will be measured using Kaplan-Meier survival analysis curves.

    Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Started3600154
Escalation phase (1)360000
Expansion phase (2)0000154
Completed3600154
Not completed000000

Outcome measures

PrimaryNumber of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose

Determine the recommended dose of omacetaxine based on the maximum tolerated dose. The MTD is defined as the highest dose at which ≤1 patient experiences a DLT in Cycle 1. Count of participants who did not experience a DLT are listed in outcome measure data table.

Time frame:
First treatment through end of Cycle 1 (28 days) only for dose escalation cohorts.
Reported as:
Count of participants · Participants
Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose
ParticipantsCohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose150000
Statistical analysis
  • Cohort 1: Escalation Phase Omacetaxine .75mg/m2 vs Cohort 0: De-Escalation Omacetaxine .5mg/m2 vs Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 vs Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Derived form number of dlts: 0.5This trial had a 3+3 study design. Escalation/de-escalation through cohorts were based on DLT events. MTD based on DLT events was determined to be 0.5mg/m2.
PrimaryOverall Response Rate

This was a pre-specified primary outcome measure defined by the proportion of patients who achieve any category of complete remission (CR, includes CR and marrow CR) or partial remission (PR) based on the 2006 International Working Group (IWG) criteria for MDS1.

Time frame:
First treatment date to study end date, or death, whichever comes first, up to 4 years.
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsCohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Overall Response Rate000070
SecondaryOverall Survival

Overall survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine to death from any cause.. This will be measured using Kaplan-Meier survival analysis curves.

Time frame:
First treatment date to study end date, or death, whichever comes first, up to 4 years.
Reported as:
Median · Days
Overall Survival
DaysCohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Overall SurvivalNA (186 to NA)900 (112 to NA)——279 (114 to 611)—
SecondaryProgression Free Survival

Progression Free Survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine that a patient lives with the disease but does not get worse. This will be measured using Kaplan-Meier survival analysis curves.

Time frame:
First treatment date to study end date, or death, whichever comes first, up to 4 years.
Reported as:
Median · Days
Progression Free Survival
DaysCohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Progression Free SurvivalNA (77 to NA)68 (40 to NA)——45 (35 to 227)—
SecondaryDuration of Response

Duration of Response will be defined as Time from documentation of tumor response to disease progression.This will be measured using Kaplan-Meier survival analysis curves.

Time frame:
First treatment date to study end date, or death, whichever comes first, up to 4 years.
Reported as:
Median · Days
Duration of Response
DaysCohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Duration of ResponseNA (109 to NA)444 (28 to NA)——313 (73 to NA)—

Adverse events

Collected over Serious Adverse Events and Other (non-serious) Adverse Events will be documented from the time the patient receives the first dose of study drug until 30 days after last study treatment, an average of 60 days. All-cause mortality is documented through study completion, an average of 4 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Escalation Phase Omacetaxine .75mg/m23/3 (100%)3/3 (100%)3/3 (100%)
Cohort 0: De-Escalation Omacetaxine .5mg/m24/6 (66.7%)3/6 (50%)6/6 (100%)
Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2———
Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2———
Cohort 4: Expansion Phase Omacetaxine .5mg/m210/15 (66.7%)13/15 (86.7%)15/15 (100%)
Cohort 5: Relapse Cohort1/4 (25%)2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Febrile NeutropeniaBlood and lymphatic system disorders2/31/6——5/151/4
Acute Kidney InjuryRenal and urinary disorders1/30/6——1/150/4
Lung InfectionRespiratory, thoracic and mediastinal disorders1/30/6——0/150/4
FeverGeneral disorders0/31/6——1/151/4
SepsisInfections and infestations0/31/6——1/151/4
Cardiac Disorders - OtherCardiac disorders0/30/6——0/151/4
Intracranial HemorrhageNervous system disorders0/30/6——0/151/4
Other, not specified in this listGeneral disorders0/31/6——0/150/4
SinusitisInfections and infestations0/31/6——0/150/4
Upper gastrointestinal hemorrhageGastrointestinal disorders0/31/6——0/150/4
Most frequent other events
Showing 10 of 202
Most frequent other events
EventCohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse Cohort
Chest Pain - CardiacCardiac disorders3/30/6——0/150/4
AnemiaBlood and lymphatic system disorders1/35/6——7/151/4
Platelet Count DecreasedInvestigations2/35/6——7/151/4
White blood cell decreasedInvestigations2/35/6——7/150/4
AnorexiaMetabolism and nutrition disorders2/32/6——2/151/4
DiarrheaGastrointestinal disorders2/30/6——1/151/4
Edema LimbsGeneral disorders2/31/6——2/151/4
HypomagnesemiaMetabolism and nutrition disorders2/31/6——2/152/4
Postnasal DripRespiratory, thoracic and mediastinal disorders2/30/6——0/150/4
ConstipationGastrointestinal disorders1/33/6——2/150/4

Baseline characteristics

Subjects were not enrolled into Cohort 2 and Cohort 3 as maximum tolerated dose was determined to be .5mg/m2.

Age, Customized
Age, Customized(Participants)Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse CohortTotal
Age >/= 18yrs36——15428
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse CohortTotal
Female13——8113
Male23——7315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse CohortTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White360015428
More than one race0000000
Unknown or Not Reported0000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Escalation Phase Omacetaxine .75mg/m2Cohort 0: De-Escalation Omacetaxine .5mg/m2Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2Cohort 4: Expansion Phase Omacetaxine .5mg/m2Cohort 5: Relapse CohortTotal
Hispanic or Latino0000101
Not Hispanic or Latino360014427
Unknown or Not Reported0000000
08

Study locations

1 site
  • Universtiy of Colorado Denver
    Aurora, Colorado 80045, United States
09

References and documents

Publications

  • Pollyea DA, Stevens BM, Abbott D, Amaya M, Gutman JA, Kent A, McMahon C, Schwartz M, Smith C, Dell-Martin J, Sohalski C, Ellis A, Haag M, Schowinsky J, Pan Z, Patel SB, Ransom M, Gillen A, Jordan CT, Pietras EM. Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial. EClinicalMedicine. 2025 Oct 10;89:103546. doi: 10.1016/j.eclinm.2025.103546. eCollection 2025 Nov. PubMed 41140451 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2025, 84 months.

Results were first posted in Sep 2026, 11 months after primary completion.

Of 68 non-industry phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 142. This study's 84 months is above that.

Counting every sponsor, half of 109 studies reached it within 78 months; a quarter within 49 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2018
First posted
Jun 21, 2018
StartActual
Sep 17, 2018
Primary completionActual
Oct 7, 2025
CompletionEst.
Jun 2027
Results first posted
Sep 29, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Sep 29, 2026 · revised Nov 6, 2026
Enrollment
28→29
Sep 29, 2026
Interventions
Arms added: Cohort 0: De-Escalation Omacetaxine .5mg/m2·Cohort 1: Escalation Phase Omacetaxine .75mg/m2·Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2·Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2·Cohort 4: Expansion Phase Omacetaxine .5mg/m2·and 1 more
All 6

Cohort 0: De-Escalation Omacetaxine .5mg/m2 · Cohort 1: Escalation Phase Omacetaxine .75mg/m2 · Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 · Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Cohort 4: Expansion Phase Omacetaxine .5mg/m2 · Cohort 5: Relapse Phase

; arms removed: Phase I·Phase II
Sep 29, 2026
Primary outcomes
Revised in 2 updates
What changed on Sep 29, 2026
  • ChangedBefore Recommended DoseNow Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated DoseTime frame: Start of study to end of study, for up to four years → Start of study through end of Cycle 1 (28 days) only for dose escalation cohorts
  • DescriptionOverall Response Rate: how it is measured was reworded
What changed on Nov 6, 2026
  • Time frameNumber of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated DoseStart of study through end of Cycle 1 (28 days) only for dose escalation cohorts → First treatment through end of Cycle 1 (28 days) only for dose escalation cohorts.
  • Time frameOverall Response RateStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
across 2 updates, Sep 29, 2026 – Nov 6, 2026
Secondary outcomes
Revised in 2 updates
What changed on Sep 29, 2026
  • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).Time frame: Start of study to end of study, up to four years
  • DescriptionOverall Survival: how it is measured was reworded
What changed on Nov 6, 2026
  • Time frameOverall SurvivalStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
  • Time frameProgression Free SurvivalStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
  • Time frameDuration of ResponseStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
  • DescriptionOverall Survival: how it is measured was reworded
across 2 updates, Sep 29, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Posted results revised
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated DoseStart of study through end of Cycle 1 (28 days) only for dose escalation cohorts → First treatment through end of Cycle 1 (28 days) only for dose escalation cohorts.
    • Time frameOverall Response RateStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
    Secondary outcomes 3 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameOverall SurvivalStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
    • Time frameProgression Free SurvivalStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
    • Time frameDuration of ResponseStudy start date to study end date, or death, whichever comes first, up to 4 years. → First treatment date to study end date, or death, whichever comes first, up to 4 years.
    • DescriptionOverall Survival: how it is measured was reworded
    + 1 other change: verification date
  2. Sep 29, 2026
    Results posted
    Enrollment 28→29
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • ChangedBefore Recommended DoseNow Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated DoseTime frame: Start of study to end of study, for up to four years → Start of study through end of Cycle 1 (28 days) only for dose escalation cohorts
    • DescriptionOverall Response Rate: how it is measured was reworded
    Secondary outcomes 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).Time frame: Start of study to end of study, up to four years
    • DescriptionOverall Survival: how it is measured was reworded
    Interventions Arms added: Cohort 0: De-Escalation Omacetaxine .5mg/m2·Cohort 1: Escalation Phase Omacetaxine .75mg/m2·Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2·Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2·Cohort 4: Expansion Phase Omacetaxine .5mg/m2·and 1 more
    All 6

    Cohort 0: De-Escalation Omacetaxine .5mg/m2 · Cohort 1: Escalation Phase Omacetaxine .75mg/m2 · Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 · Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Cohort 4: Expansion Phase Omacetaxine .5mg/m2 · Cohort 5: Relapse Phase

    ; arms removed: Phase I·Phase II
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03564873
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
Sep 17, 2018
Primary completion
Oct 7, 2025
Completion
Jun 2027 (estimated)
Results posted
Sep 29, 2026
Last update
Nov 6, 2026

Study contacts

Daniel Pollyea, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Homoharringtonine · Azacitidine

Start the discussion